Stockscreener 앱 받기
10.00
0.70%
0.07
시간 외 거래:
10.00
Relay Therapeutics Inc 주식(RLAY)의 최신 뉴스
Relay Therapeutics (RLAY) — Perceptive entities report 5.3% stake - Stock Titan
Nextech Invest Increases Relay Therapeutics Stake in Q4 2025 | Portfolio UpdateNews and Statistics - IndexBox
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. - The Motley Fool
Relay Therapeutics (RLAY) Receives a Buy from Wells Fargo - The Globe and Mail
Portfolio Update: Is Relay Therapeutics Inc a speculative investmentEarnings Growth Report & Fast Entry and Exit Trade Plans - baoquankhu1.vn
RLAY: Citizens Raises Price Target to $17, Maintains Market Outp - GuruFocus
Relay Therapeutics price target raised to $17 from $15 at Citizens - TipRanks
RLAY: Citizens Raises Price Target to $17, Maintains Market Outperform Rating | RLAY Stock News - GuruFocus
Citizens Jmp Issues Positive Forecast for Relay Therapeutics (NASDAQ:RLAY) Stock Price - MarketBeat
Relay Therapeutics (RLAY) Sees Price Target Raised by Wells Farg - GuruFocus
Wells Fargo & Company Boosts Relay Therapeutics (NASDAQ:RLAY) Price Target to $17.00 - MarketBeat
Oppenheimer reiterates Relay Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Relay Therapeutics (RLAY) Unveils Promising Phase 1/2 Trial Resu - GuruFocus
Relay Therapeutics Reports Promising Phase 3 Data for Zovegalisib + Fulvestrant in PI3Kα-Mutated HR+/HER2- Metastatic Breast Cancer at ESMO TAT 2026 12 - Minichart
Relay Therapeutics Sees Unusually Large Options Volume - National Today
Relay Therapeutics Sees Unusually Large Options Volume (NASDAQ:RLAY) - MarketBeat
Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free SurvivalWhat Does This Means For Pretreated Breast Cancer Patients? - Benzinga
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 - Bitget
Relay Therapeutics Highlights Positive Zovegalisib ReDiscover Trial Data - TipRanks
Relay Therapeutics Announces Data from Zovegalisib Plus Fulvestrant At the Phase 3 Dose of 400Mg BID Fed - marketscreener.com
Relay Therapeutics reports 11.1-month median PFS for zovegalisib 400mg BID fed in PI3Kα-mutant MBC - TradingView
Relay Therapeutics (RLAY) shows 11.1-month PFS with zovegalisib combo in PI3Kα-mutated breast cancer - Stock Titan
Relay Therapeutics moves ReDiscover regimen with zovegalisib and fulvestrant to Phase 3 trial - Traders Union
Experimental Relay cancer drug combo shows 11.1-month progression-free survival - Stock Titan
Commodore Capital Boosts Stake in Relay Therapeutics - National Today
Commodore Capital LP Raises Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Should Relay’s Zovegalisib Momentum and New Legal Forum Rules Require Action From Relay Therapeutics (RLAY) Investors? - simplywall.st
Relay Therapeutics (NASDAQ:RLAY) Reaches New 1-Year High After Analyst Upgrade - MarketBeat
Guggenheim Issues Positive Forecast for Relay Therapeutics (NASDAQ:RLAY) Stock Price - MarketBeat
Guggenheim Raises Price Target for Relay Therapeutics (RLAY) to $22 | RLAY Stock News - GuruFocus
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Relay Therapeutics (RLAY) - The Globe and Mail
Can Relay Therapeutics Inc expand into new markets2026 Market Sentiment & Growth Focused Stock Reports - baoquankhu1.vn
Relay Therapeutics Files Amended and Restated Bylaws with SEC – Key Company Information and Filing Details - Minichart
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Insider Sell: Thomas Catinazzo Sells Shares of Relay Therapeutics Inc (RLAY) - GuruFocus
Relay Therapeutics Updates Bylaws on Federal Securities Litigation - TipRanks
Relay Therapeutics (RLAY) CFO sells 17,717 shares under 10b5-1 plan - Stock Titan
Relay Therapeutics (NASDAQ: RLAY) sets federal courts for securities claims - Stock Titan
Relay Therapeutics (NASDAQ:RLAY) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Relay Therapeutics (RLAY) Soars 5.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Zovegalisib Milestones To Shape The Future Of Relay Therapeutics - RTTNews
Investment Review: Can Relay Therapeutics Inc sustain its profitability2026 Summary & Risk Managed Trade Strategies - baoquankhu1.vn
A Look At Relay Therapeutics (RLAY) Valuation After Earnings Update And New Shelf Registration - Sahm
Thomas J. Catinazzo sells 15,515 shares (NASDAQ: RLAY) in Form 144 - Stock Titan
Relay Therapeutics Experiences Revision in Stock Evaluation Amid Market Fluctuations - Markets Mojo
Wells Fargo Initiates Coverage of Relay Therapeutics (RLAY) with Equal-Weight Recommendation - MSN
Should I add Relay Therapeutics Inc stock to my portfolio2025 Technical Patterns & Weekly High Conviction Ideas - baoquankhu1.vn
Relay Therapeutics: Breakthrough Designation Sets The Stage For A Key Zovegalisib Data Catalyst - Seeking Alpha
Relay Therapeutics Stock Price Rises 6% - National Today
Relay Therapeutics (NASDAQ:RLAY) Stock Price Up 6%Should You Buy? - MarketBeat
Why Relay Therapeutics (RLAY) Is Up 14.8% After 2025 Beat, FDA Breakthrough Win for Zovegalisib - Sahm
Relay Therapeutics, Inc. (NASDAQ:RLAY) Sees Large Decrease in Short Interest - MarketBeat
Citizens reiterates Relay Therapeutics stock rating ahead of data By Investing.com - Investing.com Canada
Aug Levels: Is Relay Therapeutics Inc stock showing strong momentum2025 Analyst Calls & Smart Investment Allocation Tips - baoquankhu1.vn
RLAYRelay Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Relay Therapeutics’ Promising Path with FDA Approvals and Revenue Growth - timothysykes.com
Bank Watch: What is the earnings history of Relay Therapeutics IncWeekly Profit Summary & Growth Focused Stock Pick Reports - baoquankhu1.vn
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March - Sahm
Relay Therapeutics Surges After Breakthrough Designation for Breast Cancer Treatment - StocksToTrade
Relay Therapeutics’ Q4 Financial Performance Surges Amid Breakthrough Recognition - timothysykes.com
Relay Therapeutics (RLAY) Valuation After Breakthrough Therapy Win And Narrower Loss Attracts Fresh Investor Interest - Yahoo Finance
Relay Therapeutics (RLAY) Losses Of US$276.5 Million Test Bullish Revenue Growth Narrative - simplywall.st
Relay Therapeutics stock hits 52-week high at 9.64 USD By Investing.com - Investing.com Australia
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million - AOL.com
Relay Therapeutics, Inc. (RLAY) Stock Analysis: Exploring a 61.57% Potential Upside in Precision Medicine - DirectorsTalk Interviews
1.20%
0.06%
자본화:
|
볼륨(24시간):